In esophageal cancer staging, the radiologic approach is represented by tumor identification, preoperative staging, and re-staging after neoadjuvant therapies. At present, while barium radiography shows a high sensitivity for early and advanced tumors, endoscopy is always necessary for confirmation. CT and MRI are the gold standard for preoperative staging of advanced (T4) esophageal cancer and for evaluation of distant metastasis; however they still show a low sensitivity in the study of possible regional lymph node involvement, in differentiating residual disease and scarring; in particular the esophageal wall cannot be carefully examined.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Linking Long ncRNA to the Diagnosis, Pathogenesis, and Prognosis of Esophageal Cancer.
Dig Dis Sci
January 2025
Department of Gastroenterology and Hepatology, Loyola University Medical Center, 2160 S First Ave, Maywood, IL, 60153, USA.
Esophageal cancer is a common and often deadly malignancy, with treatment success depending largely on the stage at the time of diagnosis. Recently, studies have examined the role of non-coding RNAs in esophageal cancer pathogenesis, prognosis and therapy. This perspective specifically examines interactions long non-coding RNAs have with other RNA molecules in various facets of esophageal cancer.
View Article and Find Full Text PDFMacrophage Infiltration and ITGB2 Expression in ESCC: A Novel Correlation.
Cancer Med
January 2025
Department of Cardiothoracic Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, People's Republic of China.
Background: Esophageal squamous cell carcinoma (ESCC) is one of the most prevalent and lethal malignancies worldwide. Despite progress in immunotherapy for cancer treatment, its application and efficacy in ESCC remain limited. Therefore, there is an ongoing need to explore potential molecules and therapeutic strategies related to tumor immunity in ESCC.
View Article and Find Full Text PDFThe learning curve for laparoscopic-assisted single-port mediastinoscopic esophagectomy: an analysis of proficiency.
BMC Surg
January 2025
Department of Cardiothoracic Surgery, Fifth Affiliated Hospital of Sun Yat-Sen University, No.52 East Meihua Road, Zhuhai, Guangdong Province, 519000, China.
Background: Laparoscopic-assisted single-port mediastinoscopic esophagectomy is a safe and effective emerging minimally invasive esophagectomy, but little has been reported about the learning curve for this technology. The goal of the study was to determine the number of procedures to achieve different levels of proficiency on the learning curve.
Methods: This study retrospectively analyzed data from consecutive surgeries performed by the same surgeon at the same center from 2016 to 2021.
Treatment strategy involving docetaxel plus cisplatin and 5-fluorouracil followed by conversion surgery for locally advanced unresectable/borderline resectable esophageal squamous cell carcinoma.
Dis Esophagus
January 2025
Department of Esophageal Surgery, National Cancer Center, Tokyo, Japan.
Definitive chemoradiotherapy (dCRT) is the standard treatment for unresectable (T4) esophageal squamous cell carcinoma (ESCC), but the prognosis is poor. Borderline resectable (T3br) ESCC has been discussed, but its clinical features and appropriate treatment are unclear. The effects of docetaxel plus cisplatin and 5-fluorouracil (DCF) therapy and subsequent surgery for potentially unresectable ESCC remain controversial.
View Article and Find Full Text PDFArtificial Intelligence-Powered Human Epidermal Growth Factor Receptor 2 and Tumor Microenvironment Analysis in Human Epidermal Growth Factor Receptor 2-Amplified Metastatic Colorectal Cancer: Exploratory Analysis of Phase II TRIUMPH Trial.
JCO Precis Oncol
January 2025
Translational Research Support Office, National Cancer Center Hospital East, Chiba, Japan.
Purpose: Human epidermal growth factor receptor 2 (HER2)-targeted therapies have shown promise in treating -amplified metastatic colorectal cancer (mCRC). Identifying optimal biomarkers for treatment decisions remains challenging. This study explores the potential of artificial intelligence (AI) in predicting treatment responses to trastuzumab plus pertuzumab (TP) in patients with -amplified mCRC from the phase II TRIUMPH trial.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!